These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17199589)

  • 21. Psoriasis: the epidermal component.
    Tschachler E
    Clin Dermatol; 2007; 25(6):589-95. PubMed ID: 18021897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reviewing concepts in the immunopathogenesis of psoriasis.
    Lima Ede A; Lima Mde A
    An Bras Dermatol; 2011; 86(6):1151-8. PubMed ID: 22281904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review paper: preclinical models of psoriasis.
    Danilenko DM
    Vet Pathol; 2008 Jul; 45(4):563-75. PubMed ID: 18587106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research.
    Guttman-Yassky E; Krueger JG
    Br J Dermatol; 2007 Dec; 157(6):1103-15. PubMed ID: 17714560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphocyte-keratinocyte interactions mediated through interferon. New observations relevant to psoriasis.
    Nickoloff BJ
    Cutis; 1984 Nov; 34(5):445-6. PubMed ID: 6209070
    [No Abstract]   [Full Text] [Related]  

  • 26. Pathogenesis and therapy of psoriasis.
    Lowes MA; Bowcock AM; Krueger JG
    Nature; 2007 Feb; 445(7130):866-73. PubMed ID: 17314973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The immunopathogenesis of psoriatic disease].
    Perekhrestenko AP
    Lik Sprava; 2000; (5):10-4. PubMed ID: 11031438
    [No Abstract]   [Full Text] [Related]  

  • 28. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
    Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
    Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immunologic and genetic basis of psoriasis.
    Nickoloff BJ
    Arch Dermatol; 1999 Sep; 135(9):1104-10. PubMed ID: 10490116
    [No Abstract]   [Full Text] [Related]  

  • 30. Three decades of psoriasis research: where has it led us?
    Sabat R; Sterry W; Philipp S; Wolk K
    Clin Dermatol; 2007; 25(6):504-9. PubMed ID: 18021885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting leukocyte recruitment in the treatment of psoriasis.
    Li YY; Zollner TM; Schön MP
    Clin Dermatol; 2008; 26(5):527-38. PubMed ID: 18755372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of antikeratin 16 antibodies on the expression of Toll-like receptors 2 and 4 in keratinocytes.
    Wu C; Luan Q; Li C; Zheng Z
    Clin Exp Dermatol; 2009 Mar; 34(2):236-9. PubMed ID: 19040521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune regulation in psoriasis and psoriatic arthritis--recent developments.
    Hueber AJ; McInnes IB
    Immunol Lett; 2007 Dec; 114(2):59-65. PubMed ID: 17928070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What's new in laboratory research?
    Pincelli C; Lotti R
    J Rheumatol Suppl; 2009 Aug; 83():17-8. PubMed ID: 19661530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cytokine network in psoriasis.
    Nickoloff BJ
    Arch Dermatol; 1991 Jun; 127(6):871-84. PubMed ID: 2036036
    [No Abstract]   [Full Text] [Related]  

  • 36. Innate immune modulation of keratinocytes by antikeratin 16 antibodies.
    Wu C; Li C; Wei L; Zheng Z
    Exp Dermatol; 2008 Aug; 17(8):645-52. PubMed ID: 18557933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effects of arsenic on cutaneous and systemic immunity: focusing on CD4+ cell apoptosis in patients with arsenic-induced Bowen's disease.
    Liao WT; Yu CL; Lan CC; Lee CH; Chang CH; Chang LW; You HL; Yu HS
    Carcinogenesis; 2009 Jun; 30(6):1064-72. PubMed ID: 19376847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents.
    Sobell JM; Kalb RE; Weinberg JM
    J Drugs Dermatol; 2009 Feb; 8(2):147-54. PubMed ID: 19213230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Origin of threshold behaviour in psoriatic skin.
    Lejeune O; Simonart T
    Dermatology; 2008; 217(4):295-8. PubMed ID: 18703874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunopathogenesis of psoriasis: focus on natural killer T cells.
    Peternel S; Kastelan M
    J Eur Acad Dermatol Venereol; 2009 Oct; 23(10):1123-7. PubMed ID: 19453772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.